Prepared Remarks:

Operator

Welcome to McKesson's fourth quarter Fiscal 2023 earnings conference call. Please be advised that today's conference is being recorded. At this time, I would like to turn the call over to Nicole Kramer, manager of investor relations. Please go ahead.

Nicole Kramer -- Manager, Investor Relations

Thank you, operator. Good afternoon, and welcome, everyone, to McKesson's fourth quarter fiscal 2023 earnings call. Today, I'm joined by Brian Tyler, our chief executive officer; and Britt Vitalone, our chief financial officer. Brian will lead off followed by Britt, and then we will move to a question-and-answer session.

Today's discussion will include forward-looking statements such as forecasts about McKesson's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investor.mckesson.com and to the Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward-looking statements. Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those measures to GAAP results can be found in today's earnings release and presentation slides. The presentation slides also include a summary of our results for the quarter and guidance assumptions.

With that, let me turn it over to Brian.

Brian Tyler -- Chief Executive Officer

Thank you, Nicole, and good afternoon, everyone. I appreciate you joining us for our call today. Earlier today, we announced fourth-quarter results, closing out a very successful fiscal 2023. We delivered full-year revenues of $277 billion and adjusted earnings per diluted share of $25.94.

When excluding certain items, adjusted earnings per diluted share grew 15% from the prior year, driven by momentum across all business segments. In fiscal 2023, Team McKesson made significant progress executing our company priorities and advancing our position as a diversified healthcare services company. We grew our biopharma and oncology platforms through a balance of strategic partnerships, acquisitions, and internal investments. We delivered growth in the core distribution businesses, and we divested the majority of the operations in Europe, furthering our goal to streamline and optimize the portfolio.

As we close out fiscal 2023 and look ahead, we're confident in our ability to carry the business momentum forward, and we're excited to update and increase our long-term adjusted segment operating profit growth targets. This is a testament to our strategic focus, consistent execution, and confidence in the outlook of the business. Building off our differentiated assets and capabilities, we're well-positioned to deliver strong sustainable growth in the years ahead. Brett will later walk you through more of the financial details, including fiscal 2024 outlook and the updated long-term growth segment targets.